Why the study?
Does the transplantation of second set aortic valve allografts result in accelerated rejection compared to first set allografts in inbred rats?
Does the transplantation of second set aortic valve allografts result in accelerated rejection compared to first set allografts in inbred rats?
Cardiac valve allografts exhibit weak antigenicity, suggesting that their use for secondary valve replacement might be favorable if antigen incompatibility is minimized.
Answers are grounded in this paper and cite their sources.
May support repeat valve allograft use without accelerated rejection; leaves open human translation from this animal model.
An experimental study of transplantation of first and second set aortic valve allografts in heterotopic infrarenal aortic position in inbred rats with varying histocompatibility is described. On the 20th and 50th postoperative days, there was deposition of donor-specific antibodies on the allograft endothelia of the weakly allogeneic, non-MHC group, as evidenced by immunofluorescence studies, whereas the nonviable grafts showed no identifiable antibodies on their endothelia. The endothelia were mostly lost at day 100; previous focal mononuclear cellular infiltrates disappeared. The ground substances, however, were maintained until the 250th day. In the nonviable allografts, the media was completely acellular on the 50th day with collagen disintegration and changes in ground substance on the 100th day. Loss of endothelia and replacement by fibrin deposits with transient focal cellular infiltrations were the most significant early microscopic findings. Acellularity, fibrous neointima, and leaflet thickening due to varying degrees of fibrosis with changes in ground substance and focal infiltrations of macrophages around degenerated collagenous matrix of aortic valve allografts are the significant late changes. The second set allograft valves showed no difference in the rate or type of healing, but early degeneration while the second set skin grafts underwent accelerated rejection, thus confirming prior sensitization. This finding confirms the weak antigenicity of cardiac valve allografts. Therefore, the use of cardiac valve allografts for secondary valve replacement might be favorable if properly used. Limitation of antigen incompatibility by considering at least the ABO matching and reduction of a recipient's immunological reactivity might be a proper step to achieve a longer survival of viable allografts.
No takes yet. Share an insight, caveat, or question.
Yankah et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: